Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study

समान संसाधन

• Long‐term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib
  द्वारा: Cortes, Jorge E., और अन्य
  प्रकाशित: (2016)
• Factors influencing long‐term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib
  द्वारा: Brümmendorf, Tim H., और अन्य
  प्रकाशित: (2015)
• Pregnancy outcomes in patients treated with bosutinib
  द्वारा: Cortes, Jorge E, और अन्य
  प्रकाशित: (2020)
• Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure
  द्वारा: Khoury, H. Jean, और अन्य
  प्रकाशित: (2012)
• Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia
  द्वारा: Gambacorti-Passerini, Carlo, और अन्य
  प्रकाशित: (2014)